Alembic Pharmaceuticals Limited announced a robust performance for the second quarter and first half of FY27. Consolidated revenue for Q2 FY27 surged by 36% year-on-year to INR2,603 crores. The company also reported a significant increase in EBITDA, growing 78%. This strong financial outcome is attributed to broad-based performance across its business segments, including notable growth in the U.S. generics market.
Strong Q2 FY27 Performance
Alembic Pharmaceuticals Limited has declared its financial results for the second quarter and first half of the financial year 2027, showcasing substantial growth and improved profitability. The consolidated revenue for the second quarter (Q2 FY27) reached INR2,603 crores, marking an impressive 36% year-on-year growth. This performance was driven by strong contributions from all business verticals.
Key Financial Highlights
The company reported a significant increase in its profitability metrics. EBITDA for the quarter grew by 78%, and the EBITDA margin expanded by approximately 520 basis points, reaching 22.2% in Q2 FY27. Gross margin also saw an expansion, growing by 70 basis points year-on-year to 73.7%, attributed to a favorable product mix. For the first half of FY27, consolidated revenue grew by 31% year-on-year to INR4,753 crores.
U.S. Business Momentum
The U.S. generics segment delivered an exceptional quarter, with revenue growing by 72% year-on-year. This growth was supported by strong volume expansion in the base portfolio and meaningful contributions from recent launches. The company also highlighted the expansion of its strategic collaboration with DifGen Pharmaceuticals, aiming to enhance its complex generics portfolio in the U.S.
India Business Growth
The India business demonstrated resilience, posting a 14% year-on-year growth in the quarter, led by the Human Health division which achieved 11% growth. Growth is being supported by chronic and specialty therapies, with significant contributions from gynecology, cardiology, and emerging therapies. The specialty portfolio grew approximately 200 basis points ahead of the Indian pharmaceutical market.
Outlook for FY27
Looking ahead, Alembic Pharmaceuticals has raised its consolidated revenue growth guidance for FY27 to approximately 20% to 25%, up from the previous mid-teens indication. This revised guidance reflects increased confidence in the U.S. business, which is now expected to grow up to 40% year-on-year for the full year. The API business is also projected to achieve high teens growth. The company expects the India and ex-U.S. businesses to grow at market rate and mid-teens respectively.
Source: BSE
